ZYMEWORKS INC. Forum: Community User: Karmate1

Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results https://www.businesswire.com/news/home/20220224006052/en/Zymeworks-Provides-Corporate-Update-and-Reports-Year-End-2021-Financial-Results • Enrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). • Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting. • Financial position strengthened and cash runway extended following successful completion of equity offering in January. • Announced Chris Astle, PhD as new Chief Financial Officer, with Neil Klompas continuing as Chief Operating Officer. • Expected to exceed the previously announced workforce reduction of at least 25% by March 1, 2022, ahead of schedule. ...

https://conferencecalltranscripts.com/summary/?id=369509&pr=true

Zymeworks Announces Pricing of $100.0 Million Public Offering https://www.finance-monthly.com/2022/01/zymeworks-announces-pricing-of-100-0-million-public-offering/

Zymeworks extends losses as analysts react to restructuring, upcoming milestones https://seekingalpha.com/news/3789997-zymeworks-extends-losses-as-analysts-react-to-restructuring-upcoming-milestones Zymeworks (ZYME -12.3%) shares have set a new 52-week low after the company announced a 25% reduction in its employee headcount by the end of the year. In addition, the clinical-stage biopharmaceutical company confirmed its upcoming clinical milestones for experimental cancer therapeutics, zanidatamab, and ZW49. ...

https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-reports-inducement-grant-under-new-york-stock-exchange

https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-second-janssen-bispecific-antibody-begin/

https://www.businesswire.com/news/home/20211209005326/en/Zymeworks-Announces-Expansion-of-Zanidatamab-Pivotal-Trial-in-Asia-in-Collaboration-with-BeiGene-and-Associated-Milestone-Payment Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment • First patient dosed in South Korea under Zymeworks and BeiGene collaboration agreement • HERIZON-GEA-01 enrollment progresses with multiple active sites and continued global recruitment • Zymeworks to receive US$8MM development milestone payment from BeiGene

Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer https://www.businesswire.com/news/home/20211208006094/en/Zanidatamab-Data-Presented-at-the-San-Antonio-Breast-Cancer-Symposium-SABCS-Demonstrate-Encouraging-Antitumor-Activity-in-Heavily-Pretreated-Patients-with-HER2-Positive-Breast-Cancer • Overall confirmed objective response rate (cORR) of 36.4% and disease control rate (DCR) of 86.4% • Median progression-free survival (mPFS) of 7.3 months overall • Data support further investigation of zanidatamab plus chemotherapy as a novel therapeutic option for patients with HER2-positive metastatic breast cancer after three or more lines of prior therapy

Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms https://finance.yahoo.com/news/zymeworks-announces-second-janssen-bispecific-133000571.html

Nach den Abschlägen der letzten Tage für mich eher ein gewisser rebound (wie auch bei einigen anderen Bios). ...obwohl dann hier noch einiges mehr aufzuholen wäre 🙃

Gibt's was Neues, das den heutigen Kurssprung erklären könnte?

https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-abstract-zanidatamab-late-line-her2-positive/

Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA) https://finance.yahoo.com/news/zymeworks-launches-global-phase-3-133000747.html • HERIZON-GEA-01 study is now open and enrolling patients to evaluate zanidatamab and chemotherapy with or without tislelizumab, versus standard of care • Phase 2 data demonstrate potential benefit of zanidatamab in first-line GEA, with response rates and durability that compare favorably to both current standard of care and emerging treatments • Study design enables a potential supplemental biologics license application (BLA) for zanidatamab in first-line HER2-positive GEA as early as 2024 • Zymeworks will host a conference call and webcast at 4:15pm ET today to discuss the HERIZON‑GEA‑01 Phase 3 trial design as well as the commercial strategy in HER2‑positive gastrointestinal cancers

Zymeworks Reports 2021 Third Quarter Financial Results https://finance.yahoo.com/news/zymeworks-reports-2021-third-quarter-201500971.html